Analysts predict that Design Therapeutics, Inc. (NASDAQ:DSGN) will announce earnings of ($0.22) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Design Therapeutics’ earnings. The highest EPS estimate is ($0.21) and the lowest is ($0.22). The business is scheduled to announce its next earnings results on Tuesday, February 8th.
According to Zacks, analysts expect that Design Therapeutics will report full year earnings of ($0.83) per share for the current year, with EPS estimates ranging from ($0.86) to ($0.80). For the next financial year, analysts expect that the business will report earnings of ($1.04) per share, with EPS estimates ranging from ($1.31) to ($0.76). Zacks’ EPS calculations are an average based on a survey of research analysts that follow Design Therapeutics.
Design Therapeutics (NASDAQ:DSGN) last released its earnings results on Tuesday, November 9th. The company reported ($0.21) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.07).
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. EcoR1 Capital LLC lifted its stake in Design Therapeutics by 47.9% during the third quarter. EcoR1 Capital LLC now owns 1,863,098 shares of the company’s stock worth $27,369,000 after purchasing an additional 603,079 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Design Therapeutics by 8.9% during the third quarter. Bank of New York Mellon Corp now owns 36,476 shares of the company’s stock worth $536,000 after purchasing an additional 2,979 shares during the last quarter. Wellington Management Group LLP lifted its stake in Design Therapeutics by 1.7% during the third quarter. Wellington Management Group LLP now owns 955,588 shares of the company’s stock worth $14,037,000 after purchasing an additional 16,226 shares during the last quarter. Millennium Management LLC bought a new position in Design Therapeutics during the third quarter worth $208,000. Finally, Rock Springs Capital Management LP increased its position in Design Therapeutics by 0.6% in the third quarter. Rock Springs Capital Management LP now owns 334,050 shares of the company’s stock worth $4,907,000 after buying an additional 2,000 shares during the period. Hedge funds and other institutional investors own 50.45% of the company’s stock.
Shares of Design Therapeutics stock traded up $0.74 on Friday, hitting $15.85. 81,911 shares of the company’s stock traded hands, compared to its average volume of 80,351. The firm’s 50-day moving average is $18.44 and its 200 day moving average is $17.12. Design Therapeutics has a 52-week low of $12.52 and a 52-week high of $50.50.
Design Therapeutics Company Profile
Design Therapeutics, Inc develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company engages in the development of a program for the treatment of Friedreich's ataxia and degenerative diseases such as Fragile X syndrome and myotonic dystrophy.
Recommended Story: dividend yield calculator
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Design Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Design Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.